Clinical trials: Kidney (Renal Cell) Cancer
Kidney Cancer
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.
- Trial name
- NCT00021021
- Testing
- anti-FLT-1 ribozyme
- Where
- United States
- Sponsor
- Ribozyome
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the…
- Trial name
- NCT00041106
- Testing
- gemcitabine hydrochloride, cisplatin, gefitinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable…
- Trial name
- NCT00016939
- Testing
- alvocidib
- Where
- 101 sites in United States
- Sponsor
- SWOG Cancer Research Network
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Kidney Cancer, Renal Cell Carcinoma
A Novel Haemostatic Agent for Robotic Partial Nephrectomy
Kidney cancer is one of only a few cancers with an increasing incidence over the past two decades. Renal cell carcinoma (RCC) accounts for over 85% of all kidney tumours, which makes up 2-3% of all adult malignancies.
- Trial name
- PuraBond (NCT07284953)
- Testing
- PuraBond
- Where
- United Kingdom
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Kidney Cancer
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: When irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells.
- Trial name
- NCT00176501
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rutgers, The State University of New Jersey
Renal Cancer Cell
Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy with TKIs, in terms of median progression free survival (mPFS), in patients affected by metastatic renal cancer cell.
- Trial name
- TOKIO (NCT03456401)
- Testing
- Sorafenib or Sunitinib
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Solid Tumor
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also…
- Trial name
- TITER (NCT07166601)
- Testing
- M0324, Pembrolizumab, mFOLFIRINOX
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Oncology, Interventional Radiology
Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
This clinical feasibility evaluation is intended to further characterize and quantify the potential benefits of the FDA-cleared XR90 Augmented Reality (AR )imaging and guidance platform utilization in percutaneous soft tissue…
- Conditions
- Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma
- Trial name
- NCT07046832
- Testing
- Augmented Reality Guided Biopsy, Ultrasound Guided Biopsy
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- MediView XR, Inc.
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Multiple Myeloma
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years.
- Trial name
- NCT06623630
- Testing
- Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Skin Cancer, Kidney Transplantation
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin…
- Trial name
- NCT00133887
- Testing
- rapamycin, ciclosporine, tacrolimus
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Hospices Civils de Lyon
Clear-cell Renal Cell Carcinoma, RCC
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms.
- Conditions
- Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
- Trial name
- NCT03035630
- Testing
- Avelumab, Sunitinib
- Where
- United States
- Sponsor
- Guru Sonpavde
Clear Cell Renal Cell Carcinoma
A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma is the most common type of kidney cancer. Although new treatments such as immune checkpoint inhibitors and targeted therapies have improved outcomes for many patients, some patients with advanced…
- Trial name
- CM-BA-9 (NCT07865832)
- Testing
- CM-BA-9
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Liangyou Gu
Kidney Cancer
Erlotinib in Treating Patients With Advanced Kidney Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have advanced kidney cancer.
- Trial name
- OSI-774 (NCT00045487)
- Testing
- OSI-774
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.